Journal of Kerman University of Medical Sciences

The Role of Short-term Low-Dose Atorvastatin in Improving Endothelial Function in Normolipidemic Heart Failure with Preserved Ejection Fraction

Document Type : Original Article

Authors

Seyed Mohammad Hassan Adel 1
Saeed Yazdankhah 2
Shahla Madjidi 2
Ali Kardooni 1
Saied Hesam 3

1 Atherosclerosis Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

2 Department of Cardiology, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

3 Department of Biostatistics and Epidemiology, School of Health Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

https://doi.org/10.34172/jkmu.3575
Abstract
Background: Heart failure with preserved ejection fraction (HFpEF) imposes a heavy burden on Iran’s health system. Although therapeutics are prescribed for HFpEF, no evidence-based therapy has been generally accepted. Endothelial dysfunction is currently recognized as a promising therapeutic target for patients with HFpEF.
Methods: A total of 40 patients who referred to the echocardiography clinic of Imam Khomeini hospital in Ahvaz participated in this randomized clinical trial. Echocardiographic and clinical criteria for HFpEF and normal coronary angiography were recorded in all subjects. The patients did not have indications of statin therapy or a prior history of statin consumption. They were randomly assigned to the atorvastatin (20 mg once daily) and placebo groups (n = 20 per group). Flow-mediated dilatation (FMD) of the brachial artery was measured in the two groups before the trial and after the two-month treatment period. Clinical trial registration is available from: https://irct.behdasht.gov.ir/, (identifier: IRCT2015010320538N1).
Results: The patients’ mean age was 65 years, 40% were male, and 60% were female. There was a significant improvement in FMD only in the atorvastatin group ( + 41.5% in males and + 18.25% in females) (P < 0.001). The low-density lipoprotein (LDL) level significantly decreased after treatment in the atorvastatin group but not in the placebo group. The variation in FMD was not dramatically associated with the reduction in serum LDL in the two groups.
Conclusion: Atorvastatin has advantageous effects on the vascular endothelial function of HFpEF, and this effect is not associated with its lipid-lowering properties.

Highlights

Seyed Mohammad Hassan Adel (Google Scholar) (PubMed)

Keywords

HFpEF
Atorvastatin
Endothelial
Flow-mediated dilatation
Low-density lipoprotein
Subjects
  1. Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail. 2020;22(8):1342- 56. doi: 1002/ejhf.1858.
  2. Reddy YN, Borlaug BA. Heart failure with preserved ejection fraction. Curr Probl Cardiol. 2016;41(4):145-88. doi: 1016/j.cpcardiol.2015.12.002.
  3. Ghiadoni L, Salvetti M, Muiesan ML, Taddei S. Evaluation of endothelial function by flow mediated dilation: methodological issues and clinical importance. High Blood Press Cardiovasc Prev. 2015;22(1):17-22. doi: 1007/s40292-014-0047-2.
  4. Maruhashi T, Soga J, Fujimura N, Idei N, Mikami S, Iwamoto Y, et al. Brachial artery diameter as a marker for cardiovascular risk assessment: FMD-J study. Atherosclerosis. 2018;268:92-8. doi: 1016/j.atherosclerosis.2017.11.022.
  5. Nikolov P, Nikolova J, Orbecova M, Deneva T, Vladimirova L, Atanasova P, et al. Flow mediated vasodilation and some biomarkers of endothelial activation in pre-hypertensive objects. West Indian Med J. 2015;1(1):1-8. doi: 7727/ wimj.2015.033.
  6. Kumbhani DJ, Fonarow GC, Heidenreich PA, Schulte PJ, Lu D, Hernandez A, et al. Association between hospital volume, processes of care, and outcomes in patients admitted with heart failure: insights from get with the guidelines-heart failure. Circulation. 2018;137(16):1661-70. doi: 1161/ circulationaha.117.028077.
  7. Chamberlain AM, St Sauver JL, Gerber Y, Manemann SM, Boyd CM, Dunlay SM, et al. Multimorbidity in heart failure: a community perspective. Am J Med. 2015;128(1):38-45. doi: 1016/j.amjmed.2014.08.024.
  8. Giannitsi S, Bougiakli M, Bechlioulis A, Naka K. Endothelial dysfunction and heart failure: a review of the existing bibliography with emphasis on flow mediated dilation. JRSM Cardiovasc Dis. 2019;8:2048004019843047. doi: 1177/2048004019843047.
  9. Lam CS, Lund LH. Microvascular endothelial dysfunction in heart failure with preserved ejection fraction. Heart. 2016;102(4):257-9. doi: 1136/heartjnl-2015-308852.
  10. Oikonomou E, Siasos G, Zaromitidou M, Hatzis G, Mourouzis K, Chrysohoou C, et al. Atorvastatin treatment improves endothelial function through endothelial progenitor cells mobilization in ischemic heart failure patients. Atherosclerosis. 2015;238(2):159-64. doi: 1016/j. atherosclerosis.2014.12.014.
  11. Premer C, Kanelidis AJ, Hare JM, Schulman IH. Rethinking endothelial dysfunction as a crucial target in fighting heart failure. Mayo Clin Proc Innov Qual Outcomes. 2019;3(1):1- 13. doi: 1016/j.mayocpiqo.2018.12.006.
  12. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136(6):e137-61. doi: 1161/cir.0000000000000509.
  13. Ray KK, Kastelein JJ, Boekholdt SM, Nicholls SJ, Khaw KT, Ballantyne CM, et al. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur Heart J. 2014;35(15):960-8. doi: 1093/eurheartj/ehu107.
  14. Erbs S, Beck EB, Linke A, Adams V, Gielen S, Kränkel N, et al. High-dose rosuvastatin in chronic heart failure promotes vasculogenesis, corrects endothelial function, and improves cardiac remodeling--results from a randomized, double-blind, and placebo-controlled study. Int J Cardiol. 2011;146(1):56- 63. doi: 1016/j.ijcard.2010.02.019.
  15. Tuttolomondo A, Cirrincione A, Vassallo V, Daidone M, Pinto A. Endothelial function and pathogenesis of endothelial dysfunction. Curr Immunol Rev. 2017;13(2):115-31. doi: 2 174/1573395513666170502130828.
  16. Taddei S, Ghiadoni L, Virdis A, Versari D, Salvetti A. Mechanisms of endothelial dysfunction: clinical significance and preventive non-pharmacological therapeutic strategies. Curr Pharm Des. 2003;9(29):2385-402. doi: 2174/1381612033453866.
  17. Gladden JD, Chaanine AH, Redfield MM. Heart failure with preserved ejection fraction. Annu Rev Med. 2018;69:65-79. doi: 1146/annurev-med-041316-090654.
  18. Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart 2011;32(6):670-9. doi: 10.1093/eurheartj/ehq426.
  19. Tsujimoto T, Kajio H. Favorable effects of statins in the treatment of heart failure with preserved ejection fraction in patients without ischemic heart disease. Int J Cardiol. 2018;255:111-7. doi: 10.1016/j.ijcard.2017.12.109.
  20. Fukuta H, Goto T, Wakami K, Ohte N. The effect of statins on mortality in heart failure with preserved ejection fraction: a meta-analysis of propensity score analyses. Int J Cardiol. 2016;214:301-6. doi: 10.1016/j.ijcard.2016.03.186.
  21. Fukuta H, Little WC. Observational studies of statins in heart failure with preserved systolic function. Heart Fail Clin. 2008;4(2):209-16. doi: 10.1016/j.hfc.2008.01.005.
  22. Marti CN, Gheorghiade M, Kalogeropoulos AP, Georgiopoulou VV, Quyyumi AA, Butler J. Endothelial dysfunction, arterial stiffness, and heart failure. J Am Coll Cardiol. 2012;60(16):1455-69. doi: 10.1016/j.jacc.2011.11.082.
Journal of Kerman University of Medical Sciences
Volume 32
Pages 1-7

Home

Editorial Board

Guide for Authors

Submit Manuscript

Guide for Reviewers

Contact Us